Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–35 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PF-04383119 Clear all
Terminated Phase 3 Interventional Results available

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

NCT00809354
View directory record Official record
Conditions
Osteoarthritis, Arthritis
Interventions
NSAID, tanezumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
250
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 29, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional Results available

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

NCT00994890
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Tanezumab 2.5 mg, Tanezumab 5 mg, Tanezumab 10 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
100
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 29, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis

NCT00601484
View directory record Official record
Conditions
Cystitis, Interstitial
Interventions
PF-04383119, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Peoria, Arizona • Fresno, California • Glendora, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 29, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional Results available

Long Term Safety Study of Tanezumab in Chronic Low Back Pain

NCT00924664
View directory record Official record
Conditions
Low Back Pain
Interventions
Tanezumab 20 mg, Tanezumab 10 mg
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
149
States / cities
Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 29, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tanezumab in Adults With Chronic Low Back Pain

NCT00876187
View directory record Official record
Conditions
Low Back Pain
Interventions
Tanezumab 20 mg IV, Placebo for naproxen, Tanezumab 10 mg IV, Tanezumab 5 mg IV, Placebo for tanezumab, Naproxen
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
135
States / cities
Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 101 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 29, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously

NCT00788294
View directory record Official record
Conditions
Healthy Volunteers
Interventions
tanezumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 29, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

NCT02528188
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions
NSAID, Tanezumab 2.5 mg, Tanezumab 5 mg
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
299
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 29, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

RN624 In Adult Patients With Chronic Low Back Pain

NCT00584870
View directory record Official record
Conditions
Low Back Pain
Interventions
Naproxen, Placebo, PF-04383119 (RN624)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 29, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement

NCT02674386
View directory record Official record
Conditions
Osteoarthritis
Interventions
Investigational Medical Product (IMP) administered in parent study
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 29, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis of the Hip or Knee (2)

NCT00863304
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 29, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Tanezumab for Chronic Low Back Pain

NCT02528253
View directory record Official record
Conditions
Low Back Pain
Interventions
Placebo to Week 16; tanezumab 5mg SC, Placebo to Week 16, tanezumab 10 mg SC, Tanezumab 5 mg SC, Tanezumab 10 mg SC, Tramadol PR oral
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
179
States / cities
Birmingham, Alabama • Mobile, Alabama • Saraland, Alabama + 124 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Sep 29, 2026, 5:10 PM EDT